Multifocal AMD lens
An injectable add-on IOL is a promising alternative to telescopic implants for some patients
Howard Larkin
Published: Thursday, February 1, 2018
The Scharioth Macula Lens seems to increase near vision consistently without affecting distance visionTRIAL RESULTS In an ongoing prospective European multi-centre clinical trial launched in October 2015, 35 of a planned 60 patients so far have been implanted, of which 25 now have at least one year of follow-up. All treated patients were aged 55 or older, pseudophakic and had dry or treated wet macular degeneration that had been stable for at least six months before surgery. These patients had preoperative corrected near visual acuity ranging from 20/50 to 20/200. They also showed an improvement of at least three ETDRS lines with a +2.5D add at 40cm, and a +6.0D add at 15cm, indicating they could benefit from the magnification the lens provides, Dr Srinivasan said. Patients with active wet AMD, severe zonulopathy, iris neovascularisation, uveitis, anterior chamber depth of less than 2.8mm or previous complicated cataract surgery were excluded. Three months after surgery, mean corrected distance visual acuity was 0.18 decimal, or about 20/110 – identical with mean preoperative values. Mean uncorrected near vision acuity at 15cm was nearly 0.7, or about 20/30, three months after surgery, up from corrected near acuity values of about 0.25 with a +2.5D add at 40cm, and 0.6 with a +6.0D add at 15cm. These gains were sustained for the 25 patients with 12 months' follow-up. Intraocular pressure remained stable at 12 months in all patients, and no cases of iris capture, chafing or dislocation were reported. However, three patients reported distance vision issues including glare and halos, leading to explantation in two cases. Vitreous loss occurred during implantation in one patient. “The Scharioth Macula Lens seems to increase near vision consistently without affecting distance vision. Patient selection is key, and postoperative visual training for patients to help then to read at 15cm rather than 30 or 40cm seems to really help,” Dr Srinivasan reported. Sathish Srinivasan: sathish.srinivasan@gmail.com
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular
Long-awaited cellular therapies for corneal endothelial disease enter the clinic.
Balancing Innovation and Safety
Ensuring access to advanced cell therapies amid regulatory overhaul.
With Eyes on Its Future, ESCRS Celebrates Its Past
Winter Meeting offers opportunities to experiment with new concepts and formats.
Best of ESCRS Winter Meeting 2024
Following the New Generation
EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.
Refocus on Multifocals
Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.
Common Myths in Presbyopia Correction
Patient education key to satisfaction with refractive IOLs.
Reversible Multifocality
Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.
Managing a Cataract Surgery Refractive Miss
Weighing the pros and cons of options for intraocular intervention.
Unleashing OCT’s Full Potential
Performance of newest tool for corneal evaluation meets or beats older standard technologies.